Thermo Fisher Scientific agreed to acquire Clario Holdings for $8.88 billion in cash, aiming to integrate Clario’s endpoint data and patient‑centric clinical trial technology into Thermo’s portfolio. The deal positions Thermo to expand services across trial execution, data capture and endpoint adjudication at scale. Clario supports a large share of recent FDA approvals with endpoint services; Thermo Fisher said the acquisition will deepen its clinical insights and bolster CRO and life‑science offerings. The transaction reflects continued consolidation as service providers seek vertical integration across trial operations and data analytics. Regulators and customers will watch integration plans and potential overlap with existing Thermo assets; the acquisition underscores durable demand for clinical‑data infrastructure as biopharma sponsors prioritize streamlined, high‑quality evidence generation.